Celera Diagnostics Begins to Find its Place Within Applera | GenomeWeb

NEW YORK, July 24 – As part of Applera’s $75 million program to transform itself into a drug discovery and diagnostics powerhouse, company executives for the first time Tuesday discussed in detail how Celera Diagnostics, the newest member of the Applera family, would distinguish itself from its more well-known brethren, Celera Genomics and Applied Biosystems (ABI).

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.